Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083150 | 0.91 | TRPV1 (0.61) | MAPTTRPV1 | |
| SCHEMBL14083304 | 0.89 | MAPT (0.63) | LMNAGAAMAPTGRM4TRPV1 | |
| SCHEMBL14083382 | 0.89 | MAPT (0.59) | LMNAGAAMAPTGRM4TRPV1 | |
| SCHEMBL14083902 | 0.88 | TRPV1 (0.67) | LMNAGAAMAPTGRM4TRPV1 | |
| SCHEMBL14084057 | 0.88 | TRPV1 (0.73) | GRM4TRPV1 | |
| SCHEMBL14083484 | 0.88 | TRPV1 (0.76) | LMNAGAAMAPTGRM4TRPV1 | |
| SCHEMBL14083101 | 0.87 | MAPT (0.57) | LMNAGAAMAPTGRM4TRPV1 | |
| SCHEMBL14084053 | 0.86 | TRPV1 (0.66) | MAPTGRM4TRPV1RAB9A | |
| SCHEMBL14083126 | 0.86 | GRM4 (0.67) | LMNAMAPTGRM4TRPV1RAB9A | |
| SCHEMBL14083071 | 0.85 | MAPT (0.63) | LMNAGAAMAPTGRM4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | LMNA 2619/4885GAA 3059/4885MAPT 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.